Professional Summary

Professional Overview

Anna Kaplan is a seasoned Senior Scientist II with extensive experience in the pharmaceutical and biotechnology industry. She specializes in cutting-edge research and development, with a strong focus on innovative drug discovery and development processes.

Experience Summary

Current Role

As a Senior Scientist II at Stablix, Inc., Anna plays a pivotal role in advancing the company's research and development efforts. She is responsible for designing and executing complex experiments, analyzing data, and contributing to the development of novel therapeutic solutions. Anna's technical expertise, problem-solving skills, and collaborative approach have made her a valuable asset to the Stablix team.

Career Progression

Prior to her current role, Anna served as a Senior Scientist I at Stablix, Inc., where she made significant contributions to the company's research initiatives. Before joining Stablix, she held positions as a Senior Scientist at 858 Therapeutics and Gotham Therapeutics, where she demonstrated her ability to drive innovation and deliver impactful results.

Anna's career has been marked by a consistent progression of increasing responsibilities and leadership roles. Her experience includes conducting postdoctoral research at Columbia University, where she honed her skills in cutting-edge scientific techniques and made notable contributions to the field. She also gained valuable industry experience as a Consultant at Kyras Therapeutics, further expanding her expertise in the pharmaceutical and biotechnology sectors.

Academic Background

Anna holds a Ph.D. in Biochemistry from Columbia University in the City of New York, where she specialized in advanced molecular biology and protein engineering. Her academic achievements include several peer-reviewed publications and presentations at prestigious scientific conferences.

Areas of Expertise

• Drug discovery and development

• Protein engineering and structural biology

• Biochemical and biophysical characterization of novel compounds

• Preclinical study design and data analysis

• Cross-functional collaboration and project management

Professional Impact

Throughout her career, Anna has made significant contributions to the advancement of the pharmaceutical and biotechnology industries. Her work has resulted in the development of innovative therapeutic candidates, and she has been recognized for her ability to navigate complex scientific challenges and drive impactful research initiatives.

Conclusion

With her exceptional technical expertise, proven track record of success, and a deep commitment to scientific excellence, Anna Kaplan is poised to continue making valuable contributions to the field of drug discovery and development. Her expertise and leadership make her a valuable asset to any organization seeking to push the boundaries of pharmaceutical innovation.